Discontinuation of Phenytoin and Carbamazepine in Patients Receiving Felbamate
- 1 June 1991
- Vol. 32 (3), 398-406
- https://doi.org/10.1111/j.1528-1157.1991.tb04669.x
Abstract
Five patients participated in a controlled discontinuation of phenytoin (PHT) and carbamazepine (CBZ) after a study in which all subjects had felbamate (FBM) added to both PHT and CBZ. Four subjects (three women and 1 man aged 23-36 years) completed the protocol. Mean total seizure frequency per day with PHT and CBZ was 1.33 +/- 0.93 (mean +/- SEM), decreasing to 0.87 +/- 0.71 with addition of FBM, and 0.82 +/- 0.78 after discontinuation of PHT. Only one subject tolerated discontinuation of CBZ; the other three had dosage reductions of 33, 54, and 63%. Toxicity attributable to FBM was not observed, and patients often described less severe seizures. Results from four refractory patients indicated that FBM was able to replace PHT and reduce the need for CBZ. In addition, as PHT dosages were reduced, FBM clearance decreased 21%. As the CBZ dosages were reduced. FBM clearance decreased an additional 16.5%.Keywords
This publication has 8 references indexed in Scilit:
- Pharmacokinetics of Felbamate, a Novel Antiepileptic Drug: Application of Mixed‐Effect Modeling to Clinical TrialsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1989
- Effect of Felbamate on Phenytoin and Carbamazepine Serum ConcentrationsEpilepsia, 1989
- Felbamate Increases Phenytoin but Decreases Carbamazepine ConcentrationsEpilepsia, 1988
- Double-Blind Withdrawal of Phenytoin and Carbamazepine in Patients Treated with Progabide for Partial SeizuresEpilepsia, 1986
- Comparative Anticonvulsant Activity and Neurotoxicity of Felbamate and Four Prototype Antiepileptic Drugs in Mice and RatsEpilepsia, 1986
- Pharmacokinetics of W‐554 (ADD 03055) in Epileptic PatientsEpilepsia, 1985
- Predicting individual phenytoin dosageJournal of Pharmacokinetics and Biopharmaceutics, 1981
- Liquid-chromatographic method for simultaneous determination of phenytoin and 5-(4-hydroxyphenyl)-5-phenylhydantoin in plasma and urine.Clinical Chemistry, 1980